Concalls & earnings callsNatco Pharma Limited

Every summarised call, newest first. Latest is Q1 FY27, held 14 Aug 2026.

Latest quarter

Q1 FY27 snapshot

Strong profit growth driven by a bumper flu season in the associate Adcock Ingram and double-digit growth in the base business.

Metric	This quarter	Change
Consolidated Revenue	₹794.4 Cr	—
EBITDA Margin	30.9%	—
Consolidated PAT	₹206.5 Cr	—
Adcock Ingram Revenue	₹1,582.8 Cr	—

Latest guidance

Full-year PAT guidance of around INR750 crores.
Expect domestic business volumes to increase by about 25% this year.
Aim for Crop Health Sciences business to breakeven for the year.
Target 8 to 10 ANDA filings and 2 to 3 FTFs annually.
Expect to launch two products with exclusivity in the US in the next financial year.
Annual organic capex run rate is around INR250 crores to INR300 crores.

Said on the Q1 FY27 call.

Filed results

From filed quarterly results. YoY and QoQ compare each metric on the same accounting basis.

Quarter	Revenue	Net profit (PAT)	Basic EPS
Q3 FY25	₹474.80 Cr-37.4% YoY-65.4% QoQ	₹132.40 Cr-37.8% YoY-80.4% QoQ	₹7.43-37.5% YoY-80.3% QoQ
Q2 FY25	₹1,371.10 Cr+32.9% YoY+0.6% QoQ	₹676.50 Cr+83.3% YoY+1.2% QoQ	₹37.81+83.5% YoY+1.3% QoQ
Q1 FY25	₹1,362.60 Cr+19.5% YoY+27.5% QoQ	₹668.50 Cr+59.1% YoY+73.1% QoQ	₹37.32+60.4% YoY+73.1% QoQ
Q4 FY24	₹1,068.30 Cr+19% YoY+40.8% QoQ	₹386.30 Cr+40.1% YoY+81.6% QoQ	₹21.56+42.7% YoY+81.5% QoQ
Q3 FY24	₹758.60 Cr+54% YoY-26.4% QoQ	₹212.70 Cr+241.4% YoY-42.4% QoQ	₹11.88+248.4% YoY-42.3% QoQ

Call history